Speaker Profile
M.D., Professor, Mayo Clinic
Biography
For over 40 years, John D. Halamka, M.D., M.S., has been dedicated to the technology and policy that enable information exchange among clinical, educational and administrative stakeholders. In particular, Dr. Halamka is focused on bringing people together for multidisciplinary collaboration and career development at all levels. He works across government, academia and industry to form consortia that accelerate progress in informatics and patient care.
As Dwight and Dian Diercks President of the Mayo Clinic Platform, Dr. Halamka is currently collaborating with Young J. Juhn, M.D., M.P.H., on research addressing algorithmic bias. This work has profound implications for artificial intelligence (AI) research and health equity and is a high priority of the Mayo Clinic Platform and Mayo Clinic as a whole.
Dr. Halamka also is dedicated to educating the next generation of health care technology professionals. His expertise has given him the opportunity to teach extraordinarily diverse audiences, ranging from medical students to international policymakers. Before transitioning to Mayo Clinic, he served as a professor at Harvard Medical School for 25 years.
Dr. Halamka's research and clinical background, combined with his passion for teaching, have enabled him to implement innovative technologies in local, regional, national and international settings. During the COVID-19 pandemic, he served as co-leader of the COVID-19 Healthcare Coalition and the national convalescent plasma effort, The Fight Is In Us. He also was an active participant in Harvard's Clinical and Translational Science Awards program and was the co-principal investigator of Harvard's i2b2 project and Harvard Catalyst efforts.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
